Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION
DRKS00004741Phase 3Completed
- Sponsor
- Universitätsklinikum Düsseldorf
- Start
- Oct 2013
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised trial of trimethoprim + sulfamethoxazole, clindamycin, linezolid, flucloxacillin, cloxacillin and 3 more in Staphylococcus aureus sepsis and Staphylococcus aureus bloodstream infection (SABSI) (2 arms), sponsored by Universitätsklinikum Düsseldorf. Started Oct 2013; status: completed.
02
Drugs
trimethoprim + sulfamethoxazoleclindamycinlinezolidflucloxacillincloxacillin
03
Conditions
Staphylococcus aureus sepsisStaphylococcus aureus bloodstream infection (SABSI)
Beyond the preview
Go deeper on DRKS00004741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00004741.